Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Lung Cancer

Volumn 69, Issue 1, 2010, Pages 105-109

  Sun, Jong Mu ^a   Ahn, Myung Ju ^a   Park, Min Jae ^a   Yi, Jun Ho ^a   Kim, Tae Sung ^a   Chung, Myung Jin ^a   Park, Yeon Hee ^a   Ahn, Jin Seok ^a   Park, Keunchil ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Erlotinib; Gefitinib; Guideline; Non small cell lung cancer; Response criteria

Indexed keywords

BEVACIZUMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; PEMETREXED; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR;

ACCURACY; ARTICLE; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; HUMAN; LUNG NON SMALL CELL CANCER; LYMPH NODE METASTASIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR VOLUME; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; LUNG NEOPLASMS; LYMPH NODE; PATHOLOGY; PRACTICE GUIDELINE; REPRODUCIBILITY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HUMANS; LUNG NEOPLASMS; LYMPH NODES; PRACTICE GUIDELINES AS TOPIC; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; REPRODUCIBILITY OF RESULTS; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 77953356224     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.09.014     Document Type: Article

References (17)

1. Miller A.B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer 1981, 47:207-214.
2. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
3. Moskowitz C.S., Jia X., Schwartz L.H., Gonen M. A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer 2009, 45:300-310.
4. Sargent D.J., Rubinstein L., Schwartz L., Dancey J.E., Gatsonis C., Dodd L.E., et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009, 45:290-299.
5. Bogaerts J., Ford R., Sargent D., Schwartz L.H., Rubinstein L., Lacombe D., et al. Individual patient data analysis to assess modifications to the RECIST criteria. Eur J Cancer 2009, 45:248-260.
6. Dancey J.E., Dodd L.E., Ford R., Kaplan R., Mooney M., Rubinstein L., et al. Recommendations for the assessment of progression in randomised cancer treatment trials. Eur J Cancer 2009, 45:281-289.
7. Schwartz L.H., Bogaerts J., Ford R., Shankar L., Therasse P., Gwyther S., et al. Evaluation of lymph nodes with RECIST 1.1. Eur J Cancer 2009, 45:261-267.
8. Kobayashi J., Kitamura S. Evaluation of mediastinal lymph nodes by computed tomography in lung cancer. Nihon Kyobu Shikkan Gakkai Zasshi 1992, 30(Suppl.):247-253.
9. Kamiyoshihara M., Kawashima O., Ishikawa S., Morishita Y. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. J Cardiovasc Surg (Torino) 2001, 42:119-124.
10. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
11. Thatcher N., Chang A., Parikh P., Rodrigues Pereira J., Ciuleanu T., von Pawel J., et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005, 366:1527-1537.
12. Sequist L.V., Martins R.G., Spigel D., Grunberg S.M., Spira A., Janne P.A., et al. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008, 26:2442-2449.
13. Inoue A., Kobayashi K., Usui K., Maemondo M., Okinaga S., Mikami I., et al. First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy. J Clin Oncol 2009, 27:1394-1400.
14. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
15. Schwartz L.H., Colville J.A., Ginsberg M.S., Wang L., Mazumdar M., Kalaigian J., et al. Measuring tumor response and shape change on CT: esophageal cancer as a paradigm. Ann Oncol 2006, 17:1018-1023.
16. Glazer G.M., Gross B.H., Quint L.E., Francis I.R., Bookstein F.L., Orringer M.B. Normal mediastinal lymph nodes: number and size according to American Thoracic Society mapping. AJR Am J Roentgenol 1985, 144:261-265.
17. Hanna N., Shepherd F.A., Fossella F.V., Pereira J.R., De Marinis F., von Pawel J., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004, 22:1589-1597.